Synovus Financial Corp Has $1.29 Million Position in Aetna (AET)
Synovus Financial Corp cut its holdings in shares of Aetna (NYSE:AET) by 4.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,638 shares of the company’s stock after selling 381 shares during the quarter. Synovus Financial Corp’s holdings in Aetna were worth $1,290,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Farallon Capital Management LLC purchased a new position in Aetna during the fourth quarter worth about $940,734,000. OppenheimerFunds Inc. lifted its position in Aetna by 1.3% during the fourth quarter. OppenheimerFunds Inc. now owns 3,279,841 shares of the company’s stock worth $591,650,000 after buying an additional 41,616 shares during the period. Wells Fargo & Company MN lifted its position in Aetna by 101.0% during the first quarter. Wells Fargo & Company MN now owns 2,797,748 shares of the company’s stock worth $472,819,000 after buying an additional 1,405,859 shares during the period. Deutsche Bank AG lifted its position in Aetna by 57.5% during the fourth quarter. Deutsche Bank AG now owns 2,704,723 shares of the company’s stock worth $487,900,000 after buying an additional 987,156 shares during the period. Finally, Diamond Hill Capital Management Inc. lifted its position in Aetna by 5.1% during the first quarter. Diamond Hill Capital Management Inc. now owns 1,715,322 shares of the company’s stock worth $289,890,000 after buying an additional 82,492 shares during the period. Hedge funds and other institutional investors own 87.01% of the company’s stock.
Several equities analysts recently weighed in on the company. Cantor Fitzgerald upgraded Aetna from a “neutral” rating to an “overweight” rating in a research report on Tuesday, May 1st. Credit Suisse Group reduced their target price on Aetna from $208.00 to $194.00 and set a “neutral” rating on the stock in a research report on Monday. Piper Jaffray reiterated a “buy” rating and set a $212.00 target price on shares of Aetna in a research report on Tuesday, January 30th. Zacks Investment Research upgraded Aetna from a “sell” rating to a “hold” rating in a research report on Thursday, May 3rd. Finally, ValuEngine upgraded Aetna from a “hold” rating to a “buy” rating in a research report on Friday, February 2nd. Eight research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $190.29.
Aetna (NYSE:AET) last released its quarterly earnings data on Tuesday, May 1st. The company reported $3.19 EPS for the quarter, topping analysts’ consensus estimates of $2.97 by $0.22. The company had revenue of $15.34 billion for the quarter, compared to the consensus estimate of $15.32 billion. Aetna had a return on equity of 21.42% and a net margin of 5.76%. The company’s quarterly revenue was up 1.1% compared to the same quarter last year. During the same period last year, the business posted $2.71 EPS. equities analysts forecast that Aetna will post 11.06 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, April 27th. Investors of record on Thursday, April 12th were issued a dividend of $0.50 per share. The ex-dividend date of this dividend was Wednesday, April 11th. This represents a $2.00 annualized dividend and a dividend yield of 1.13%. Aetna’s payout ratio is currently 20.28%.
Aetna Company Profile
Aetna Inc operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment offers medical, pharmacy benefit management service, dental, behavioral health, and vision plans on an insured and employer-funded basis.
Receive News & Ratings for Aetna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aetna and related companies with MarketBeat.com's FREE daily email newsletter.